Kairos Pharma (KAPA) Operating Expenses (2023 - 2025)

Kairos Pharma (KAPA) has reported Operating Expenses for 3 consecutive years, with $1.5 million the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, Operating Expenses rose 555.86% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2025 stood at $4.6 million (up 141.43% YoY), and the FY2025 full-year result was $5.6 million, up 137.81% from the prior year.
• Operating Expenses grew to $1.5 million in Q2 2025 per KAPA's latest filing, from $1.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $1.5 million in Q2 2025 and bottomed at $222000.0 in Q2 2024.
• Historically, Operating Expenses has averaged $804500.0 across 3 years, with a median of $736000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses jumped 32.78% in 2024, then soared 555.86% in 2025.
• Over 3 years, Operating Expenses stood at $1.1 million in 2023, then jumped by 32.78% to $1.4 million in 2024, then advanced by 0.69% to $1.5 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $1.5 million, $1.3 million, and $1.4 million for Q2 2025, Q1 2025, and Q4 2024 respectively.